← Back to Screener
Cognition Therapeutics, Inc. Common Stock (CGTX)
Price$1.29
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)-33.79%
Price vs S&P 500 (4W)6.62%
VGM Score83.19
Market Capitalization$115.45M
All Metrics
Book Value / Share (Quarterly)$0.33
P/TBV (Annual)0.76x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.23
Price vs S&P 500 (YTD)-12.60%
EPS (TTM)$-0.26
10-Day Avg Trading Volume1.40M
EPS Excl Extra (TTM)$-0.26
EPS (Annual)$-0.32
ROI (Annual)-68.53%
Cash / Share (Quarterly)$0.35
ROA (Last FY)-48.54%
EBITD / Share (TTM)$-0.54
ROE (5Y Avg)-86.22%
Cash Flow / Share (Annual)$-0.28
P/B Ratio3.86x
P/B Ratio (Quarterly)2.27x
Net Income / Employee (Annual)$-1,677,600
Net Interest Coverage (TTM)-1805.69x
ROA (TTM)-53.07%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)3.45x
Quick Ratio (Quarterly)5.76x
3-Month Avg Trading Volume1.10M
52-Week Price Return344.67%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.95
52-Week High$3.83
EPS Excl Extra (Annual)$-0.32
CapEx CAGR (5Y)-50.89%
26-Week Price Return-25.86%
Quick Ratio (Annual)3.37x
13-Week Price Return24.04%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.92x
Enterprise Value$84.32M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.41
3-Month Return Std Dev123.40%
Net Income / Employee (TTM)$-1,398,400
ROE (Last FY)-68.53%
Net Interest Coverage (Annual)-1125.69x
EPS Basic Excl Extra (Annual)$-0.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.26
ROI (TTM)-72.65%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.39
Price vs S&P 500 (52W)320.31%
Year-to-Date Return-4.44%
5-Day Price Return3.20%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-59.30%
Month-to-Date Return9.32%
Cash Flow / Share (TTM)$-0.79
EBITD / Share (Annual)$-0.66
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-86.22%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)1.06x
P/B Ratio (Annual)3.48x
Book Value / Share (Annual)$0.39
Price vs S&P 500 (13W)15.78%
Beta1.77x
Revenue / Share (TTM)$0.00
ROE (TTM)-72.68%
52-Week Low$0.25
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.05est. -0.07
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CGTXCognition Therapeutics, Inc. Common Stock | — | — | A | $1.29 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for age-related degenerative diseases of the central nervous system and retina. Its lead candidate, CT1812, is an oral antagonist designed to cross the blood-brain barrier and selectively bind to the S2R complex. The company is advancing this approach through clinical development.